|
| August 14, 2019 |
Ribociclib With Endocrine
Therapy Prolongs Survival in Advanced Breast Cancer
Cyclin-dependent kinase 4/6 inhibitors interrupt signaling that leads to cell-cycle progression and cancer growth in advanced hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. Recently, the role of one of these drugs, ribociclib (in conjugation with endocrine therapy), was evaluated in a clinical trial that focused on overall survival. Read more. |
|
|
Effect of Transgender Status on Breast-Cancer Risk
While breast cancer in males is relatively uncommon, little is known about the risk in transgender persons. A retrospective, nationwide cohort study from the Netherlands sought to help address this lack of information. Data gathered from medical records from the VU University Medical Center in Amsterdam were used to follow 2,260 transgender women and 1,229 transgender men for a median person-time of 13 years and 8 years, respectively.
Read more. |
|
Mental Illness and Adherence
to Endocrine Therapy
In women with estrogen receptor–positive breast cancer, endocrine therapy can significantly decrease mortality. Patients with mental illness, however, are often nonadherent to prescribed treatment regimens, and noncompliance in this population can be catastrophic. Data from the Surveillance, Epidemiology, and End Results Medicare database were examined to determine the prevalence and influence of preexisting mental illness on adherence to endocrine therapy. Read more. |
|
|
Connect With U.S. Pharmacist
    |
|
|
|
|
